KHANH TOAN NGUYEN^*, THI HUONG PHAM, VAN LAM NGO, VAN TUAN BUI, VAN NHAT NGUYEN, THI PHUONG THAO NGUYEN, THI KHANH HA NGUYEN, THI THUY VAN NGUYEN

Oncology Research, Vol.33, No.7, pp. 1667-1677, 2025, DOI:10.32604/or.2025.061905 - 26 June 2025

Abstract Aims: The study aimed to evaluate the effectiveness and adverse events of tyrosine kinase inhibitors (TKIs) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: A retrospective study on advanced NSCLC patients with EGFR mutations treated with TKIs as a first-line therapy at Nghe An Oncology Hospital, Vietnam between January 2017 and August 2023. The primary endpoints included objective response rate, progression-free survival, and tolerability. The secondary endpoint was overall survival. Results: A total of 211 patients received first-line treatment with Erlotinib (n = 74), Gefitinib (n… More >

Colleen Crangle^1,2,*, Bude Piccin², Lara Hyde³, Elin Östman⁴

Journal of Intelligent Medicine and Healthcare, Vol.1, No.2, pp. 91-102, 2022, DOI:10.32604/jimh.2022.038379 - 05 January 2023

Abstract Postprandial glucose responses provide vital information on an individual’s risk of major diet-related chronic diseases. This study features digital health technology, namely Continuous Glucose Monitoring (CGM) sensors, along with mobile devices (iPhones running an app) used to collect data from individuals and their environment, specifically nutritional information on what they eat and drink. The paper presents a retrospective analysis of data collected during an investigation into the use of a functional drink taken as a supplement with a standardized meal to reduce postprandial responses to that meal. Given that there are consequential differences between individuals… More >

Shuai Liu^*†1, Lu Lu^*†1, Feng Pan^‡, Chunsheng Yang^*†, Jing Liang^§, Jinfeng Liu^¶, Jian Wang^#, Rong Shen^**, Fu-Ze Xin^††, Nan Zhang^*†

Oncology Research, Vol.29, No.1, pp. 25-31, 2021, DOI:10.3727/096504022X16427607626672

Abstract Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival… More >

Stefania Nobili^*, Daniele Lavacchi^†, Gabriele Perrone^*, Giulio Vicini^†, Renato Tassi^‡1, Ida Landini^*, AnnaMaria Grosso^§, Giandomenico Roviello^*¶, Roberto Mazzanti^‡, Carmine Santomaggio^¶2, Enrico Mini^*¶

Oncology Research, Vol.28, No.3, pp. 237-248, 2020, DOI:10.3727/096504019X15755437099308

Abstract The use of vinorelbine as a single agent or in combination regimens in non-small cell lung cancer (NSCLC) is associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectable or metastatic NSCLC patients, according to real-world treatment patterns, has still not been widely explored. Eighty-one patients treated at a single institution were retrospectively analyzed. Thirty-seven received standard first-line single-agent vinorelbine, and 44 received vinorelbine plus platinum drugs, based on physician’s choice; 61.7% were older than 70 years, and 60.5% were affected by 2 comorbidities. Sixty-three patients were evaluable for… More >

Rohini K. Hernandez¹, Karynsa Cetin¹, Melissa Pirolli², Jane Quigley², David Quach², Paul Smith³, Scott Stryker¹, Alexander Liede¹

Canadian Journal of Urology, Vol.22, No.4, pp. 7858-7864, 2015

Abstract Introduction: Canadian guidelines define castration-resistant prostate cancer (CRPC) at high risk of developing metastases using PSA doubling time (PSADT) <8 months, whereby men may be offered more frequent bone scans/imaging. We evaluated PSA data from nonmetastatic (M0) prostate cancer patients treated at urology and oncology clinics across the United States (US) to describe the proportion and characteristics of patients who met CRPC and high-risk criteria.
Materials and methods: We identified M0 prostate cancer patients aged ≥18 years receiving androgen deprivation therapy (ADT) in 2011 from electronic health records (EHR), covering 129 urology and 64 oncology practices across… More >